| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On November 12, 2026, Elicio Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on two proposals, each of wh... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and pa... |
| 14 Sep 2026 |
8-K: Shareholder Director Nominations; Other Events
To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K “Notice of Annual Meeting” is incorporated by reference into this Item 5.08. |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS sm... |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of July 1, 2026, between Elicio Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it... |
| 24 Jun 2026 |
8-K: Regulation FD Disclosure
AMPLIFY-7P Defining the Path Forward for ELI-002 7P in Metastatic mKRAS PDAC JUNE 24, 2026 |
| 17 Jun 2026 |
8-K: Other Events
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer • 100% confirmed complete radiographic and complete metabolic resp... |
| 15 Jun 2026 |
8-K: Other Events
AMPLIFY-7P Defining the Path Forward for ELI-002 7P in Adjuvant mKRAS PDAC JUNE 15, 2026 |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates • In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven ... |
| 16 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
ELICIO THERAPEUTICS, INC. Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement March 16, 2026 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 JonesTrading Institutional Services LLC 325 Hud... |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates • Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic duct... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease pro... |
| 17 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapy |
| 12 Aug 2025 |
8-K: Other Events
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients • At extended median follow-up of 19.7 months, medi... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in panc... |
| 05 Aug 2025 |
8-K: Other Events
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI- 002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis • The AMPLIFY-7P study of ELI-002 7P successfully passes event-dr... |
| 04 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
Execution Version NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (the “Agreement”) is made as of June 3, 2025, by and among Elicio Therapeutics, Inc., a Delaware corporation (the “Company”), and GKCC, LLC, a Delaware limited liabil... |
| 20 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 19, 2025, Elicio Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on two proposals, each of which w... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY- 7P clinical trial expected in Q3 2025 Company has al... |
| 31 Mar 2025 |
8-K: Results of Operations and Financial Condition
�� � !"#!$ !!$ %�&#'() *+*, *+*( -". /01023452... |
Loading...